AKT1 and colorectal carcinoma: Dihydroartemisinin (Figure 2, 17), a derivative of artemisinin, demonstrates potent antitumor effects through inducing programmed cell death, suppressing neoplastic growth, and impeding cellular proliferation and motility (Olatunde et al., 2023; Chen and Yao, 2023) found that dihydroartemisinin effectively curtailed CRC RKO cell proliferation and migration while stimulating apoptosis through G2/M phase cell cycle arrest, which mechanism involves suppression of PI3K/AKT signaling pathway activation, evidenced by reduced phosphorylation of p38 MAPK, PI3K, and AKT proteins.